New drugs in prostate cancer
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-06-01
|
| Series: | Prostate International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888216300216 |
| _version_ | 1797758607378350080 |
|---|---|
| author | Sangjun Yoo Se Young Choi Dalsan You Choung-Soo Kim |
| author_facet | Sangjun Yoo Se Young Choi Dalsan You Choung-Soo Kim |
| author_sort | Sangjun Yoo |
| collection | DOAJ |
| description | The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms. |
| first_indexed | 2024-03-12T18:31:27Z |
| format | Article |
| id | doaj.art-ec6ff7f74ef84ec486496785dc8eb903 |
| institution | Directory Open Access Journal |
| issn | 2287-8882 |
| language | English |
| last_indexed | 2024-03-12T18:31:27Z |
| publishDate | 2016-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Prostate International |
| spelling | doaj.art-ec6ff7f74ef84ec486496785dc8eb9032023-08-02T08:18:10ZengElsevierProstate International2287-88822016-06-0142374210.1016/j.prnil.2016.05.001New drugs in prostate cancerSangjun YooSe Young ChoiDalsan YouChoung-Soo KimThe standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.http://www.sciencedirect.com/science/article/pii/S2287888216300216Castration ResistantDrugsDrug TherapyInvestigationalProstatic Neoplasm |
| spellingShingle | Sangjun Yoo Se Young Choi Dalsan You Choung-Soo Kim New drugs in prostate cancer Prostate International Castration Resistant Drugs Drug Therapy Investigational Prostatic Neoplasm |
| title | New drugs in prostate cancer |
| title_full | New drugs in prostate cancer |
| title_fullStr | New drugs in prostate cancer |
| title_full_unstemmed | New drugs in prostate cancer |
| title_short | New drugs in prostate cancer |
| title_sort | new drugs in prostate cancer |
| topic | Castration Resistant Drugs Drug Therapy Investigational Prostatic Neoplasm |
| url | http://www.sciencedirect.com/science/article/pii/S2287888216300216 |
| work_keys_str_mv | AT sangjunyoo newdrugsinprostatecancer AT seyoungchoi newdrugsinprostatecancer AT dalsanyou newdrugsinprostatecancer AT choungsookim newdrugsinprostatecancer |